ag-1296 has been researched along with Symptom Cluster in 1 studies
6,7-dimethoxy-3-phenylquinoxaline: ATP-competitive inhibitor of receptor kinase
| Excerpt | Relevance | Reference |
|---|---|---|
| "The standard treatment for acute promyelocytic leukemia (APL) involves differentiation therapy with retinoic acid (RA)." | 1.35 | Inhibiting the platelet derived growth factor receptor increases signs of retinoic acid syndrome in myeloid differentiated HL-60 cells. ( Bunaciu, RP; Reiterer, G; Smith, JL; Yen, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reiterer, G | 1 |
| Bunaciu, RP | 1 |
| Smith, JL | 1 |
| Yen, A | 1 |
1 other study available for ag-1296 and Symptom Cluster
| Article | Year |
|---|---|
Inhibiting the platelet derived growth factor receptor increases signs of retinoic acid syndrome in myeloid differentiated HL-60 cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CD18 Antigens; Cell Different | 2008 |